In this presentation, Anand A. Patel, MD, reviewed the contemporary standard-of-care treatment roadmap for AML in 2025, covering key phases like induction chemotherapy (eg, the “7+3” regimen), consolidation…
Eunice S. Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, New York, discusses the treatment strategies for patients who develop secondary acute myeloid leukemia (AML) following hypomethylating agent…
NEW YORK (Reuters Health) – After a standard course of combination chemotherapy for advanced non-small-cell lung cancer, maintenance therapy with a single agent improves overall survival and progression-free…
NEW YORK (Reuters Health) – Patients with advanced non-small-cell lung cancer have higher response rates to a regimen that includes an albumin-bound formulation of paclitaxel (nab-paclitaxel) than solvent-based…
NEW YORK (Reuters Health) – Depending on the treatment they received, survivors of childhood cancer may require long-term follow-up because of an elevated risk of symptomatic cardiac events,…
NEW YORK (Reuters Health) – Daily low-dose aspirin reduces not only cardiovascular mortality but also nonvascular mortality – and cancer mortality in particular — after relatively short duration…
NEW YORK (Reuters Health) – A systematic review and meta-analysis provides “reasonable” support for the current practice of giving adjuvant therapy to patients with resected biliary tract cancer…
NEW YORK (Reuters Health) – Progression-free survival (PFS) is significantly longer in women with recurrent ovarian cancer when bevacizumab is added to chemotherapy, a multicenter team reports in…
NEW YORK (Reuters Health) – Cancer patients given pegfilgrastim experience less bone pain if they take naproxen 500 mg twice daily for about a week, according to the…
NEW YORK (Reuters Health) – Adding trastuzumab (Herceptin) to standard chemotherapy for HER2-positive early breast cancer significantly reduces recurrence risk and improves overall survival, but it also increases…
NEW YORK (Reuters Health) – Adding cladribine to the standard induction regimen for adults with acute myeloid leukemia (AML) increases the complete remission rate and consequent survival, a…
NEW YORK (Reuters Health) – Adding bevacizumab (Avastin, Genentech) to standard carboplatin and paclitaxel chemotherapy offers little clinical benefit in patients aged 65 and older with non-small cell…
